Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae in a Neonatal Intensive Care Unit in China

References

• Perez F, El Chakhtoura NG, Papp-Wallace KM, et al. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin Pharmacother. 2016;17(6):761–781. doi:10.1517/14656566.2016.114565826799840
   PubMed Web of Science ®Google Scholar
• Ding Y, Wang Y, Hsia Y, et al. Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China. Ann Clin Microbiol Antimicrob. 2019;18(1):36. doi:10.1186/s12941-019-0334-931727088
   PubMed Web of Science ®Google Scholar
• Diaz A, Ortiz DC, Trujillo M, et al. Clinical characteristics of Carbapenem-resistant Klebsiella pneumoniae infections in ill and colonized children in Colombia. Pediatr Infect Dis J. 2016;35(3):237–241. doi:10.1097/INF.000000000000098726569194
   PubMed Web of Science ®Google Scholar
• Folgori L, Bielicki J. Future challenges in pediatric and neonatal sepsis: emerging pathogens and antimicrobial resistance. J Pediatr Intensive Care. 2019;8(1):17–24. doi:10.1055/s-0038-167753531073504
   PubMed Web of Science ®Google Scholar
• Esposito EP, Gaiarsa S, Del Franco M, et al. A novel IncA/C1 group conjugative plasmid, encoding VIM-1 metallo-beta-lactamase, mediates the acquisition of Carbapenem resistance in ST104 Klebsiella pneumoniae isolates from neonates in the intensive care unit of V.Monaldi hospital in Naples. Front Microbiol. 2017;8:2135. doi:10.3389/fmicb.2017.0213529163422
   PubMed Web of Science ®Google Scholar
• Logan LK, Renschler JP, Gandra S, et al. Carbapenem-Resistant Enterobacteriaceae in children, United States, 1999–2012. Emerg Infect Dis. 2015;21(11):2014–2021. doi:10.3201/eid2111.15054826486124
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen J, Liu Y, et al. In vitro activities of Ceftaroline/avibactam, Ceftazidime/avibactam, and other comparators against pathogens from various complicated infections in China. Clin Infect Dis. 2018;67(suppl_2):S206–S16. doi:10.1093/cid/ciy65930423043
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, de Jonge BLM, Stone GG, et al. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15. J Antimicrob Chemother. 2018;73(10):2777–2781. doi:10.1093/jac/dky26730010951
   PubMed Web of Science ®Google Scholar
• Potter RF, D’Souza AW, Dantas G. The rapid spread of carbapenem-resistant Enterobacteriaceae. Drug Resist Updat. 2016;29:30–46. doi:10.1016/j.drup.2016.09.00227912842
   PubMed Web of Science ®Google Scholar
• Sharma R, Park TE, Moy S. Ceftazidime-avibactam: a novel Cephalosporin/ beta-lactamase inhibitor combination for the treatment of resistant gram-negative organisms. Clin Ther. 2016;38(3):431–444. doi:10.1016/j.clinthera.2016.01.01826948862
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against Carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883–17. doi:10.1128/AAC.00883-1728559250
   PubMed Web of Science ®Google Scholar
• Bradley JS, Armstrong J, Arrieta A, et al. Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of Ceftazidime-avibactam in hospitalized pediatric patients. Antimicrob Agents Chemother. 2016;60(10):6252–6259. doi:10.1128/AAC.00862-1627503642
   PubMed Web of Science ®Google Scholar
• Iosifidis E, Chorafa E, Agakidou E, et al. Use of Ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children <5 years of age. Pediatr Infect Dis J. 2019;38(8):812–815. doi:10.1097/INF.000000000000234431135647
   PubMed Web of Science ®Google Scholar
• Gaibani P, Campoli C, Lewis RE, et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother. 2018;73(6):1525–1529. doi:10.1093/jac/dky08229566151
   PubMed Web of Science ®Google Scholar
• Gottig S, Frank D, Mungo E, et al. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. J Antimicrob Chemother. 2019;74(1):3211–3216. doi:10.1093/jac/dkz33031365094
   PubMed Web of Science ®Google Scholar
• Both A, Buttner H, Huang J, et al. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother. 2017;72(9):2483–2488. doi:10.1093/jac/dkx17928637339
   PubMed Web of Science ®Google Scholar
• Chiotos K, Han JH, Tamma PD. Carbapenem-resistant Enterobacteriaceae infections in children. Curr Infect Dis Rep. 2016;18(1):2. doi:10.1007/s11908-015-0510-926711126
   PubMed Web of Science ®Google Scholar
• Seifert H, Korber-Irrgang B, Kresken M, et al. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. Int J Antimicrob Agents. 2018;51(2):227–234. doi:10.1016/j.ijantimicag.2017.06.02428705666
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 30th CLSI supplement M100 Wayne, PA: CLSI; 2020
   Google Scholar
• Sweden: European committee on antimicrobial susceptibility testing; 2018 Available from: http://www.eucast.org/clinical_breakpoints/. Accessed 824.
   Google Scholar
• Tian D, Pan F, Wang C, et al. Resistance phenotype and clinical molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae among pediatric patients in Shanghai. Infect Drug Resist. 2018;11:1935–1943. doi:10.2147/IDR.S17558430498365
   PubMed Web of Science ®Google Scholar
• Guo Y, Hu F, Zhu D, et al. Antimicrobial resistance changes of carbapenem-resistant Enterobacteriaceae strains isolated from children. Zhonghua Er Ke Za Zhi. 2018;12:907–914.
   Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328. doi:10.1128/AAC.02166-1324514083
   PubMed Web of Science ®Google Scholar
• Sutherland CA, Nicolau DP. Susceptibility profile of Ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals. Clin Ther. 2015;37(7):1564–1571. doi:10.1016/j.clinthera.2015.05.50126088525
   PubMed Web of Science ®Google Scholar
• Yin D, Wu S, Yang Y, et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of Ceftazidime-avibactam and Ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(4):e02431–18. doi:10.1128/AAC.02431-1830617091
   PubMed Web of Science ®Google Scholar
• Zhang P, Shi Q, Hu H, et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect. 2020;26(1):124.e1–124.e4. doi:10.1016/j.cmi.2019.08.020
   Web of Science ®Google Scholar
• Wang B, Pan F, Wang C, et al. Molecular epidemiology of Carbapenem-resistant Klebsiella pneumoniae in a paediatric hospital in China. Int J Infect Dis. 2020;93:311–319. doi:10.1016/j.ijid.2020.02.00932068096
   PubMed Web of Science ®Google Scholar
• Nour I, Eldegla HE, Nasef N, et al. Risk factors and clinical outcomes for carbapenem-resistant Gram-negative late-onset sepsis in a neonatal intensive care unit. J Hosp Infect. 2017;97(1):52–58. doi:10.1016/j.jhin.2017.05.02528583886
   PubMed Web of Science ®Google Scholar
• Nichols WW, de Jonge BL, Kazmierczak KM, et al. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to Ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother. 2016;60(8):4743–4749. doi:10.1128/AAC.00220-1627216074
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang X, Wang J, et al. Phenotypic and genotypic characterization of Carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012–2016). Clin Infect Dis. 2018;67(suppl_2):S196–S205. doi:10.1093/cid/ciy66030423057
   PubMed Web of Science ®Google Scholar
• Dong F, Zhang Y, Yao K, et al. Epidemiology of Carbapenem-resistant Klebsiella pneumoniae bloodstream infections in a Chinese children’s hospital: predominance of New Delhi metallo-beta-lactamase-1. Microb Drug Resist. 2018;24(2):154–160. doi:10.1089/mdr.2017.003128594635
   PubMed Web of Science ®Google Scholar
• Logan LK, Weinstein RA. The epidemiology of Carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36. doi:10.1093/infdis/jiw28228375512
   PubMed Web of Science ®Google Scholar
• Giddins MJ, Macesic N, Annavajhala MK, et al. Successive emergence of Ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018;62(3):e02101–e02117. doi:10.1128/AAC.02101-1729263067
   PubMed Web of Science ®Google Scholar
• Viau R, Frank KM, Jacobs MR, et al. Intestinal carriage of Carbapenemase-producing organisms: current status of surveillance methods. Clin Microbiol Rev. 2016;29(1):1–27. doi:10.1128/CMR.00108-1426511484
   PubMed Web of Science ®Google Scholar
• Humphries RM, Hemarajata P. Resistance to Ceftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3. Antimicrob Agents Chemother. 2017;61(6):e00536–17. doi:10.1128/AAC.00537-1728438937
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim YA, Kim D, et al. Risk factors of community-onset extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia in South Korea using National Health Insurance claims data. Int J Antimicrob Agents. 2019;54(6):723–727. doi:10.1016/j.ijantimicag.2019.09.00531520781
   PubMed Web of Science ®Google Scholar